Ginkgo Bioworks Hldgs Inc (DNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2002 | 12-2001 | 09-2001 | 06-2001 | 03-2001 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 89,129 | 395,203 | 392,529 | 373,568 | 581,939 |
| Marketable Securities | 911,080 | 952,875 | 1,107,914 | 1,019,238 | 750,134 |
| Receivables | 336,245 | 315,340 | 309,054 | 272,680 | 269,570 |
| Inventories | 359,254 | 356,946 | 340,069 | 316,319 | 294,620 |
| Income taxes - deferred | N/A | 139,567 | 42,379 | 50,903 | 51,021 |
| Other current assets | 0 | 22,567 | 0 | 0 | 0 |
| TOTAL | $1,892,806 | $2,221,394 | $2,230,485 | $2,078,022 | $1,983,099 |
| Non-Current Assets | |||||
| PPE Net | 907,813 | 865,668 | 797,146 | 790,504 | 765,176 |
| Investments And Advances | 1,452,582 | 1,516,813 | 1,022,419 | 1,208,305 | 974,873 |
| Intangibles | 2,376,624 | 2,415,792 | 2,495,283 | 2,573,156 | 2,656,792 |
| Other Non-Current Assets | 204,461 | 127,222 | 320,299 | 243,121 | 220,415 |
| TOTAL | $4,941,480 | $4,925,495 | $4,635,147 | $4,815,086 | $4,617,256 |
| Total Assets | $6,834,286 | $7,146,889 | $6,865,633 | $6,893,108 | $6,600,355 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 149,692 | 149,692 | 149,692 | 149,692 |
| Accounts payable and accrued liabilities | 53,120 | 33,348 | 24,304 | 24,838 | 24,321 |
| Accrued Expenses | N/A | 45,259 | N/A | N/A | N/A |
| Other current liabilities | N/A | N/A | N/A | 386,918 | N/A |
| TOTAL | $504,359 | $663,797 | $643,789 | $561,448 | $548,317 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | 19,543 | N/A | N/A | N/A |
| Other Non-Current Liabilities | 21,417 | 47,431 | 69,935 | 139,114 | 90,535 |
| TOTAL | $505,382 | $563,273 | $413,997 | $511,655 | $376,196 |
| Total Liabilities | $1,009,741 | $1,227,070 | $1,057,786 | $1,073,103 | $924,513 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,051,152 | 1,055,588 | 1,054,406 | 1,054,958 | 1,052,795 |
| Common Shares | 10,512 | 10,566 | 10,544 | 10,550 | 10,528 |
| Retained earnings | -1,234,238 | -1,197,300 | -1,235,011 | -1,253,956 | -1,292,603 |
| Other shareholders' equity | 266,373 | 311,722 | 291,276 | 330,843 | 271,152 |
| TOTAL | $5,824,545 | $5,919,819 | $5,807,847 | $5,820,005 | $5,675,842 |
| Total Liabilities And Equity | $6,834,286 | $7,146,889 | $6,865,633 | $6,893,108 | $6,600,355 |